NasdaqGM:NTLABiotechs
Why Intellia Therapeutics (NTLA) Is Up 14.2% After FDA Lifts MAGNITUDE Trial Holds and Upgrade
In early April 2026, Intellia Therapeutics received an upgrade from Jones Trading after the FDA lifted clinical holds on its MAGNITUDE and MAGNITUDE-2 ATTR trials, restoring regulatory clarity following a patient death deemed likely unrelated to the company’s treatment.
This renewed regulatory confidence, alongside expectations for key HAELO Phase 3 data, highlights how safety assessments can critically reshape perceptions of Intellia’s CRISPR pipeline and commercial pathway.
With clinical...